Turn Therapeutics (TTRX) Liabilities and Shareholders Equity (2024 - 2026)

Turn Therapeutics' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $18.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $18.6 million; the TTM figure through Mar 2026 stood at $35.1 million (changed N/A YoY), while the FY2025 annual figure was $12.2 million, up 493.6% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $18.6 million, up from $12.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $18.6 million in Q1 2026, with the low at $2.0 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $8.2 million (2025), against an average of $9.3 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 493.6% in 2025, while the deepest fall reached 493.6% in 2025.
• Turn Therapeutics' Liabilities and Shareholders Equity stood at $2.0 million in 2024, then soared by 493.6% to $12.2 million in 2025, then soared by 53.3% to $18.6 million in 2026.
• Business Quant data shows TTRX's Liabilities and Shareholders Equity at $18.6 million in Q1 2026, $12.2 million in Q4 2025, and $4.3 million in Q3 2025.